Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG

Leuven, Belgium, Boston, MA, US - March 17, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian transparency legislation1, it had received two transparency notifications following the closing of its private placement, which was announced on March 7, 2022.

Oxurion received a transparency notification dated March 14, 2022, from Fidelity Management & Research Company LLC, indicating that, by virtue of an acquisition of shares on March 7, 2022, through the private placement, it had acquired 3,128,819 common shares, which represents 6.7% of Oxurion’s voting rights, and thus crossed the 5% threshold (the “Fidelity Notification”).

Oxurion also received a transparency notification dated March 15, 2022, from Novartis Pharma AG and Novartis AG, which confirmed Novartis Pharma AG’s holding of 2,177,226 common shares, which as a result of the private placement now represents 4.7% of Oxurion’s voting rights, and thereby also crossed the 5% threshold (downwards) (the “Novartis Notification”).

Content of the Fidelity NotificationReason of the notificationsAcquisition or disposal of voting securities or voting rights.

Notifications byA parent undertaking or a controlling person.

Persons subject to the notification requirement

Date on which the threshold is crossed7 March 2022

Threshold that is crossed5%

Denominator46,628,892

Notified detailsSee Annex 1.

Chain of controlled undertakings through which the holding is effectively heldFidelity Management & Research Company LLC is controlled by FMR LLC. FMR LLC is not a controlled entity.

Content of the Novartis Notification Reason of the notificationsPassive crossing of a threshold.

Notifications byA parent undertaking or a controlling person.

Persons subject to the notification requirement

Date on which the threshold is crossed7 March 2022

Threshold that is crossed5%

Denominator46,628,892

Notified detailsSee Annex 2.

Chain of controlled undertakings through which the holding is effectively heldNovartis Pharma AG is a wholly-owned direct subsidiary of Novartis AG.

About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For more information, please contact:

Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief Business OfficerTel: +32 479 783 583michael.dillen@oxurion.com

EUMEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel: +44 20 7638 9571oxurion@medistrava.com USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com

ANNEX 1

ANNEX 2

1 Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

Attachment